Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
展开▼
机译：公开了与肿瘤相关抗原（TaAs）结合的T细胞受体（TCR）用于靶向癌细胞，表达该癌细胞的T细胞，其制备方法以及用于治疗使用该癌症的方法。公开了是TCR和它们的变体，其与HLA类I或II分子与肽结合，例如MAG-003具有KVLEHVVRV（SEQ ID NO：1）的氨基酸序列。本说明书进一步涉及用于免疫治疗方法的肽，蛋白质，核酸，细胞，癌症的免疫疗法和肿瘤相关的T细胞肽表位，单独或与其他可以例如用于的其他肿瘤相关肽组合疫苗组合物的活性药物成分，刺激抗肿瘤免疫应答，或刺激T细胞离体并转移到患者中。与主要组织相容性复合物（MHC）的分子结合的肽，或肽，也可以是抗体，可溶性T细胞受体和其他结合分子的靶标。
展开▼
